Indiana University
CRIOs and their equivalents often are asked to bridge academic and provider sides of institutions to support clinical trials and data analytics with massive research datasets.Â
Presence of cfDNA, CTCs Predicts Recurrence in Triple-Negative Breast Cancer
Analyzing both circulating tumor DNA and circulating tumor cells, investigators could classify patients into groups with significantly higher and lower recurrence risk.
LifeOmic, IU's Komen Tissue Bank Integrate Platforms to Further Breast Cancer Research
The Komen Tissue Bank will use LifeOmic's Precision Health Cloud platform for genomic, clinical, and imaging data aggregation and analysis, among other things.
Foundation Medicine's ctDNA assay was able to subclassify patients into higher and lower recurrence risk groups with CTCs providing an additional boost.
NIH Announces Upcoming Genomic Medicine Studies
The trials are part of the second phase of the Implementing Genomics in Practice program, which is slated to receive $42 million in funding over 5 years.